CRS is the most common and potentially most serious adverse event after the reinfusion of CAR T-cells; if CRS can be effectively controlled, anti-CD19 CAR T-cell therapy is extremely safe and effective. This evidence concerns the gene CD19 and congenital rubella syndrome.